CS Medica Future Growth
Future criteria checks 2/6
CS Medica is forecast to grow earnings and revenue by 48.6% and 46.9% per annum respectively while EPS is expected to grow by 55.4% per annum.
Key information
48.6%
Earnings growth rate
55.4%
EPS growth rate
Pharmaceuticals earnings growth | 21.2% |
Revenue growth rate | 46.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 04 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2027 | 75 | N/A | N/A | N/A | 1 |
9/30/2026 | 54 | -3 | -3 | 0 | 1 |
9/30/2025 | 34 | -9 | -10 | -7 | 1 |
9/30/2024 | 16 | -15 | -20 | -17 | 1 |
6/30/2024 | 5 | -12 | -4 | 0 | N/A |
3/31/2024 | 5 | -13 | -5 | -1 | N/A |
12/31/2023 | 3 | -14 | -8 | -5 | N/A |
9/30/2023 | 1 | -15 | -11 | -8 | N/A |
6/30/2023 | 10 | -11 | -12 | -9 | N/A |
3/31/2023 | 11 | -11 | -16 | -15 | N/A |
12/31/2022 | 11 | -12 | -17 | -15 | N/A |
9/30/2022 | 11 | -11 | -17 | -14 | N/A |
6/30/2022 | 4 | -10 | -20 | -17 | N/A |
3/31/2022 | 3 | -5 | -17 | -11 | N/A |
12/31/2021 | 3 | -2 | -12 | -8 | N/A |
9/30/2021 | 3 | 1 | -10 | -6 | N/A |
6/30/2021 | 1 | 0 | -4 | 1 | N/A |
9/30/2020 | 2 | 0 | -1 | 1 | N/A |
9/30/2019 | 1 | 0 | 0 | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8G8 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 8G8 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 8G8 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 8G8's revenue (46.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 8G8's revenue (46.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 8G8's Return on Equity is forecast to be high in 3 years time